Comparison of IAC and IA regimens in acute myeloid leukaemia initial induction therapy the clinical efficacy and safety of the multi center, randomized, controlled phase III clinical study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005466

Enrollment

Unknown

Registered

2014-11-10

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukaemia

Interventions

A:IAC

B:Idarubicin, arabinoside (10mg)

C:Idarubicin, arabinoside (12mg)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the AML (except M3) diagnostic criteria (FAB detection, immune markers, chromosome, gene), and for the early treatment of patients with; 2. To be aged from 18 to 60; 3. The ECOG 0-3 class score; 4. Primary or secondary AML; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. In patients with chronic myelogenous leukemia, other myeloproliferative disease into the AML; 2. Acute promyelocytic leukemia (M3); 3. With other advances in malignant tumor; 4. Can't control in patients with severe sepsis and other diseases in patients with severe intolerance to chemotherapy; 5. Patients with cardiac dysfunction: ejection fraction (EF) less than 30%, NYHA standard, above the heart function not entire grade II; 6. Liver, kidney insufficiency patients: serum bilirubin (SB) more than 2mg/dl, AST more than 2.5 times the upper limit of normal, serum creatinine (SCr), 2.5mg/dl; 7. refuse to Signed informed consent.

Design outcomes

Primary

Measure	Time frame
complete remission;	—

Contacts

Public ContactWu Depei

wudepei@medmail.com.cn+86 13951102021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026